2026 ICD-10-CM Diagnosis Code D81.82Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]

ICD-10-CM Codes›D50–D89›D80-D89›D81

ICD-10-CM D81.82
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D81.82 is a billable ICD-10-CM diagnosis code for activated Phosphoinositide 3-kinase Delta Syndrome [APDS]. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 808 through 810. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Immunity disorders.

Code Identity

ICD-10-CM Code
D81.82
Billable Status
Yes — Valid for Submission
Code Describes
Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
Short Description
Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
Same as the full description in the CMS dataset.
Parent Code
D81.8
Other combined immunodeficiencies

Code Classification

ChapterD50–D89Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
SectionD80-D89Certain disorders involving the immune mechanism
CategoryD81Combined immunodeficiencies
This CodeD81.82Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency PASLI disease

Code Also

  • , if applicable, any associated manifestations, such as:
  • bronchiectasis J47
  • herpes virus infections B00
  • other acute respiratory tract infections J00 J06 J20 J22
  • other infections A00 B99
  • pneumonia J12 J18

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Disease, diseased
      • p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]
    • Syndrome
      • activated phosphoinositide 3-kinase delta syndrome [APDS]

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR BLD008
Immunity disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Code History & ChangesHistory

Replacement D81.82 replaces the following previously assigned code(s):

  • D81.89 - Other combined immunodeficiencies
FY 2023AddedAdded to the ICD-10-CM code setEffective October 1, 2022.
FY 2024–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D81.82Overview

Is D81.82 (Other combined immunodeficiencies) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report activated Phosphoinositide 3-kinase Delta Syndrome [APDS] on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D81.82 group to?

When activated Phosphoinositide 3-kinase Delta Syndrome [APDS] is the principal diagnosis on an inpatient stay, it groups to MS-DRG 808, 809, 810, with relative weights from 1.0466 to 2.2079 depending on complications. Higher weights mean higher Medicare reimbursement.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.